BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting trypsin-like enzymes, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting elastase or for generally inhibiting serine
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting trypsin-like enzymes, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting elastase or for generally inhibiting serine
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting trypsin-like enzymes, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting elastase or for generally inhibiting serine
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods based on enzyme inhibition.
BACKGROUND OF THE INVENTION
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods deriving from enzyme inhibition.
BACKGROUND
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in which proteins
TECHNICAL FIELD
This invention relates to compounds and methods for enzyme inhibition. In particular, the invention relates to therapeutic methods deriving from enzyme inhibition.
BACKGROUND
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in which proteins
Den mest komplette database med medicinske urter understøttet af videnskab
Arbejder på 55 sprog
Urtekurer, der understøttes af videnskab
Urtegenkendelse ved billede
Interaktivt GPS-kort - tag urter på stedet (kommer snart)
Læs videnskabelige publikationer relateret til din søgning
Søg medicinske urter efter deres virkninger
Organiser dine interesser og hold dig opdateret med nyhedsundersøgelser, kliniske forsøg og patenter
Skriv et symptom eller en sygdom, og læs om urter, der kan hjælpe, skriv en urt og se sygdomme og symptomer, den bruges mod. * Al information er baseret på offentliggjort videnskabelig forskning